Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and aims</h3><p>Fatty liver causes premature death worldwide and requires long‐term health care. We examined relationships of liver disease markers, including patatin‐like phospholipase domain‐containing protein 3 (<i>PNPLA3</i>) I148M, with mortality in the U.S. National Health and Nutrition Examination Survey, 1988‐1994, with 27 years of linked mortality data. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We studied 13,298 viral hepatitis negative adults who fasted at least 4 hours using the non‐alcoholic fatty liver disease (NAFLD) liver fat score and NAFLD fibrosis score. <i>PNPLA3</i> I148M was genotyped in a subgroup of participants from 1991 to 1994 (N=5,640). Participants were passively followed for mortality, identified by death certificate underlying or contributing causes, by linkage to the National Death Index through 2015. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>During follow‐up (median, 23.2 years), cumulative mortality was 33.2% overall and 1.1% with liver disease, including primary liver cancer. Increased liver disease mortality was associated with <i>PNPLA3</i> I148M (hazard ratio (HR), 2.9; 95% confidence interval (CI), 0.9‐9.8) and 148M genotypes (HR, 18.2; 95% CI, 3.5‐93.8), an intermediate (HR, 3.8; 95% CI, 1.3‐10.7) or high (HR, 12.6; 95% CI, 4.3‐36.3) NAFLD liver fat score, and a high NAFLD fibrosis score (HR, 12.2; 95% CI, 1.9‐80.6) adjusted for risk factors. Survival curves suggest that the increased mortality risk with two 148M alleles was greatest beginning in the second decade of follow‐up. Overall, but not cardiovascular disease, mortality was associated with the <i>PNPLA3</i> 148M allele, and both mortality outcomes were associated with higher fat and fibrosis scores. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>In the U.S. population, <i>PNPLA3</i> I148M and higher NAFLD liver fat and fibrosis scores were associated with increased liver disease mortality. Genetic variant <i>PNPLA3</i> I148M may complement other liver disease markers for NAFLD surveillance. </p></section>

Clinical Utility of Genetic Variants in PNPLA3 and TM6SF2 to Predict Liver‐Related Events in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Differential effects of genetic polymorphism on comorbid disease in metabolic dysfunction-associated steatotic liver disease

Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population

The greater impact of PNPLA3 polymorphism on liver-related events in Japanese non-alcoholic fatty liver disease patients: A multicentre cohort study

Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Integrating PNPLA3 into clinical risk prediction

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD

Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus

Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease

Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype

PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease

Combination of risk alleles of PNPLA3, TM6SF2, and HSD17B13 of donors can predict recurrence of steatotic liver disease after liver transplantation

Epidemiological Study on the Interaction between the PNPLA3 (rs738409) and Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease

Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up

Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease

Prevalence and determinants of liver disease in relatives of Italian patients with advanced MASLD

Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population

Hepatic inflammation and fibrosis are profiles related to mid‐term mortality in biopsy‐proven MASLD: A multicenter study in Japan

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis